CASI Pharmaceuticals Files 6-K, Incorporates into F-3 Filings
Ticker: CASIF · Form: 6-K · Filed: Aug 27, 2025 · CIK: 1962738
Sentiment: neutral
Topics: filing-update, registration-statement
TL;DR
CASI Pharma filed a 6-K, just procedural stuff incorporating into F-3s. No new news.
AI Summary
CASI Pharmaceuticals, Inc. filed a Form 6-K on August 27, 2025, to report information for the month of August 2025. The filing is incorporated by reference into the company's existing Registration Statements on Form F-3, specifically File Nos. 333-283998 and 333-281621.
Why It Matters
This filing serves as an update and incorporates previous disclosures into ongoing registration statements, which is a standard procedural step for companies with active offerings or shelf registrations.
Risk Assessment
Risk Level: low — This filing is a routine procedural update and does not contain new material financial or operational information.
Key Players & Entities
- CASI Pharmaceuticals, Inc. (company) — Filer
- 333-283998 (dollar_amount) — Registration Statement File Number
- 333-281621 (dollar_amount) — Registration Statement File Number
FAQ
What is the purpose of this Form 6-K filing?
The purpose of this Form 6-K filing is to report information for the month of August 2025 and to incorporate this information by reference into the Company's Registration Statements on Form F-3.
What are the file numbers for the Registration Statements on Form F-3 mentioned in the filing?
The file numbers for the Registration Statements on Form F-3 mentioned are 333-283998 and 333-281621.
What is the principal executive office address of CASI Pharmaceuticals, Inc.?
The principal executive office address is 1701-1702, China Central Office Tower 1, No. 81 Jianguo Road, Chaoyang District, Beijing, 100025, People's Republic of China.
What is the SIC code for CASI Pharmaceuticals, Inc.?
The Standard Industrial Classification (SIC) code for CASI Pharmaceuticals, Inc. is 2834, which corresponds to Pharmaceutical Preparations.
Does CASI Pharmaceuticals, Inc. file annual reports under Form 20-F or Form 40-F?
The registrant indicates it files annual reports under Form 20-F.
Filing Stats: 815 words · 3 min read · ~3 pages · Grade level 14.6 · Accepted 2025-08-27 16:30:17
Filing Documents
- tm2524476d1_6k.htm (6-K) — 15KB
- 0001104659-25-084032.txt ( ) — 16KB
Forward-Looking Statements
Forward-Looking Statements This announcement contains forward-looking statements. These statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking "intends," "plans," "believes," "estimates," "confident" and similar statements. Among other things, the business outlook and quotations from management in this announcement, as well as the Company's strategic and operational plans, contain forward-looking statements. The Company may also make written or oral forward-looking statements in its periodic reports to the U.S. Securities and Exchange Commission (the "SEC"), in its annual report to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Statements that are not historical facts, including statements about the Company's beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of factors could cause actual results to differ materially from those contained in any forward-looking herein is as of the date of this announcement, and the Company undertakes no obligation to update any forward-looking statement, except as required under applicable law. We caution readers not to place undue reliance on any forward-looking statements contained herein. EVOMELA ® is proprietary to Acrotech Biopharma Inc. and its affiliates. FOLOTYN ® is proprietary to Acrotech Biopharma Inc and its affiliates. The Company is currently involved in disputes and legal proceedings related to certain pipe
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. CASI Pharmaceuticals, Inc. By: /s/ David Cory Name: David Cory Title: CEO Date: August 27, 2025